BIOFORCE NANOSCIENCES HOLDINGS, INC. Annual Report Summary

I’ve put together this guide to help you understand how BioForce Nanosciences Holdings, Inc. (BFNH) performed this year. My goal is to explain their financial filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

BioForce sells nutritional supplements like vitamins and protein powders under the "BioForce Eclipse" brand. They operate as a virtual brand, meaning they do not own manufacturing facilities. Instead, a third-party manufacturer in Virginia produces and packages their products.

BioForce does not own the rights to these specific formulas. Because they lack exclusive agreements, their manufacturer is permitted to sell the same products to other companies. This means BioForce competes in a crowded market without a unique product advantage.

2. Financial Health: The "Going Concern" Warning

The company is in a difficult financial position. As of December 31, 2025, they reported $786 in assets against $618,522 in debt.

Because the company recorded zero revenue in 2022 and 2023, auditors issued a "going concern" warning. This indicates significant doubt regarding the company's ability to continue operations over the next year. They currently operate on a consignment basis, which allows them to avoid paying for inventory until it is sold. While this preserves cash, it limits their ability to scale or control their supply chain.

3. Strategy and Challenges

• The Pivot: The company transitioned away from its former nanotechnology business to focus entirely on health and wellness. They target "Baby Boomers" interested in longevity supplements and fitness enthusiasts.
• Marketing: Growth efforts are currently limited to low-cost strategies, including social media, trade shows, and online sales. Management aims to secure shelf space in physical stores and utilize eco-friendly packaging to differentiate their brand.
• The Hurdle: They face intense competition from established brands with significantly larger marketing budgets. Without unique products or exclusive contracts, acquiring new customers remains a costly and difficult process.

4. Leadership and Structure

The company maintains a lean structure with three full-time employees and utilizes office space provided by a board member to minimize overhead. They own a subsidiary called Element Global, Inc. and are currently exploring the potential acquisition of its assets. These discussions are in the early stages.

5. Key Risks

• Financial Survival: The risk of insolvency is high. With liabilities vastly exceeding their assets, the company requires external funding to sustain operations.
• Lack of Competitive Moat: Because they use generic formulas, they have limited control over pricing. Larger competitors can easily undercut them on cost.
• Stock Dilution: To address debt obligations, the company issued 4.25 million new shares to directors and officers in early 2025. This increases the total share count, which reduces the ownership percentage and potential value of existing shares.

6. Future Outlook

BioForce is currently operating as a startup with no recent sales history. Their future depends on their ability to convert marketing efforts into consistent revenue and secure new capital. Without a major cash injection or a breakthrough in distribution, the company faces a high risk of failure.

Note: This report is based on the latest 10-K filing. Given the significant gap between assets and debts, please exercise extreme caution when evaluating this as an investment.